Condition
TDP-43 Proteinopathies
Total Trials
6
Recruiting
3
Active
3
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
Early P 1 (1)
P 2 (2)
Trial Status
Recruiting3
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT05744310Not ApplicableRecruiting
Effects of Long Term Ventilation Support on the Quality of Life of ALS Patients and Their Families
NCT06891716Early Phase 1Recruiting
[18F]ACI-19626 PET in TDP-43 Proteinopathies
NCT04937452Phase 2Completed
Dopaminergic Therapy for Frontotemporal Dementia Patients
NCT06596746Recruiting
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
NCT03127514Phase 2Completed
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT02860338Completed
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
Showing all 6 trials